Axon myelination is significantly disrupted in patients with Alzheimer's disease. Researchers also found brain cells of men and women vary significantly in how their genes respond to the neurodegenerative disease.
An international research team revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta).
Researchers report a lifelong accumulation of amyloid plaques in the brain could contribute to Alzheimer's disease.
A new study reports amyloid plaques are present shortly after brain injury in middle aged people. The findings may help explain why people who suffer TBIs are at an increased risk for developing Alzheimer's.
Blood samples taken from people enrolled in an Alzheimer's research study revealed higher levels of phosphorylated tau 217 that correlated with the presence of amyloid plaques. People with amyloid in their brains had up to three times more of the tau protein in their blood than those who had no evidence of amyloid accumulation. The higher levels of the protein were evident even in people with no signs of cognitive decline.
Researchers have successfully measured a significant difference between the brains of patients with an inherited form of Alzheimer's disease and their healthy family members who do not carry the genetic mutation for the disease.
Researchers have identified biomarkers for Alzheimer's disease which accurately predict the development of the disease years prior to symptoms developing.
Animal study reveals the formation of amyloid plaques drives brain tissue loss and neurodegeneration in Alzheimer's disease. However, lithium, a drug commonly used to treat bipolar disorder, reduces the life-shortening effects of the loss.
Bexarotene, an anti-cancer drug which is about to be tested in a clinical trial as a potential treatment for Alzheimer's disease, fails to reduce amyloid plagues; according to researchers replicating the original study.
Researchers report an antibiotic usually administered prior to surgery to prevent infection could help reduce damage to the brain that occurs during the early stages of Alzheimer's disease.
A newly developed antibody has shown to trigger a meaningful reduction of amyloid beta in patients with early stage Alzheimer's disease.